November 18, 2016 7:42am

 

… After the see-saw of advance/decline lines, who wants to be too long over a weekend?

Forget a glass half full or half empty, I want a glass  to have a drink…

 

 

I answer one question; in which company should investors put, keep and commit their money!

 

 

If you are not a subscriber, you won’t know the morning’s indications and who is in the headlights.

 

I write in every line that investors need to avoid risks as if I were the first to be hurt if I am wrong!

 

RegMed Investors’ (RMi) provides exclusive and original content; put your eyes on the page to figure out what’s really going on!

 

 

I keep track of closes, indexes and pricing as news lately lacks any energy as the social media impact of RMi reporting stimulates the reality of “our” universe as well as disrupting element in the trading of sector equities!

Remember, yesterday’s dog is today’s hero!

 

 

BUY: BTX

SELL:  AST, BSTG and KOOL

 

Indexes and ETFs: The IBB (+0.11%), IWM (+0.18%) while the XLV and XBI are NOT indicating

Dow futures are UP +0.02% and NASDAQ futures are UP +0.09%

 

U.S. stock index futures pointed to a lower open on Friday as traders eyed a host of Fed speakers.

European stocks were lower in morning trade as rising U.S. bond yields pushed the dollar to a more than 13-and-a-half-year high as investors upped bets on a December rate hike.

Asia markets were mixed, with the Japanese market climbing to an 11-month high on the back of a relatively weaker yen.

 

Data docket: leading indicators released at 10 a.m. ET.

  • Kansas City Fed President Esther George is set to speak in Houston at a joint conference of the Federal Reserve Banks of Dallas and Kansas City at 9:30 a.m. ET, with Dallas Fed President Rob Kaplan speaking there at 1:30 p.m. ET, while New York Fed President Bill Dudley will hold a press briefing at 9:30 a.m. ET. Chicago Fed President Charles Evans and Fed Governor Jerome Powell are also slated to speak.

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) sector closed POSITIVE on Thursday, NEGATIVE Wednesday and Tuesday, POSITIVE on Monday and last Friday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

·         Thursday closed POSITIVE with 15 decliners, 28 advancers and 0 flats;

·         Wednesday closed NEGATIVE with 26 decliners, 13 advancers and 4 flats;

·         Tuesday closed NEGATIVE with 27 decliners, 13 advancers and 3 flats;

·         Monday closed POSITIVE with 17 decliners, 22 advancers and 4 flats;

·         Last Friday closed POSITIVE with 10 decliners, 30 advancers and 3 flats;

 

 

Remembering Thursday’s closing investor letter, “The theme of the week was the skirmish of oversold and overbought as “power perceived is power achieved” in relation to share pricing and value.”

…. Vulnerability is today’s buzz word!

  • “Our” universe is always in some sort of sentiment pain, as the sharply up and painfully down syndrome seems never leaves.

Positive news is always good but, it is usually fleeting, something to be sold into after the “pop”. Back to my thesis, catalysts and milestones are the “secret sauce” of pricing reality!

  • We are also getting closer to year’s end and tax selling could come early unlike Santa!

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

·         The iShares Nasdaq Biotechnology (IBB) closed  Thursday up +0.70% and is UP +0.11% in Friday’s pre-market;

·         The SPDR S&P Biotech ETF (XBI) closed Thursday up +1.48% and is NOT indicating in Friday pre-market;

·         The Health Care Select Sector SPDR ETF (XLV) closed up +0.40% Thursday and is NOT indicating in Friday’s pre-market;

·         The iShares Russell 2000 (IWM) closed up +0.76% on Thursday and is UP +0.18% in Friday’s pre-market.

 

 

Companies in my headlights:

Asterias Biotherapeutics (NYSEMKT: AST) closed UP again +$0.65 to $5.45 after Wednesday’s $4.80 (+$0.40). Since 11/8’s $3.05 to 11/15’s <Tuesday> $4.40, a target is being formed for a trading incentive – Maintaining SELL;

BioTime (NYSEMKT: BTX) closed UP +$0.05 to $3.60. BTX announces details of 'positive data' from its Renevia pivotal trial, reported via a presentation at the 14th annual International Federation for Adipose Therapeutics and Science meeting. Developed as an alternative for whole adipose tissue fat transfer procedures, Renevia is designed to mimic the naturally-occurring extracellular matrix and provide a 3-D scaffold that enables effective cell transplant and engraftment. In the run-in portion of this trial, the Renevia administration procedure was found to be reproducible, and the pivotal trial is now into its controlled phase. Encouraging signs of Renevia being able to promote new tissue generation were seen with the run-in practice patients. If the pivotal trial is successful, BTX plans to file the data as the basis for the issuance of CE marking for European use. CE marking is anticipated as early as the second half of 2017. New is usually a pricing stimulant for BTX - BUY

Biostage (BSTG) closed UP +$0.02 to $0.823. The day’s range was $0.76 to $0.84 while the range from 11/3 was $0.75 to $0.87. After the conference call, what do they have – nothing other than a desperately needed offering - post past year’s financings of $1.95 and $1.76 – what will be the price of the next financing be $0.50 to $0.60 and 100% warrant coverage <hopefully registered, this time> or is a reverse split to be exacted to protect the NASDAQ listing – the aren’t many options. As I had stated – too bad, BSTG HAS a therapeutic approach but, they haven’t been able to sell it to investors! What solid or named investor would step-up to rally the future … to be taken down by yet another severely discounted offering and dilution? Show me the market moving tangibles as I do favor the CEO and company but, the realities “stink” – Maintaining SELL;

Cesca Therapeutics (KOOL) closed UP +$0.24 to $3.39. KOOL is getting too rich for my needs and a target for profit taking. In the past six days, the shares have appreciated for $2.77, with KOOL we are always drinking from a half-empty glass – SELL;

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.